ESBRIET (pirfenidone), immunosuppressant
PULMONOLOGY - Focus
Opinions on drugs -
Posted on
Jun 26 2015
Reason for request
-
Minor improvement in the treatment of idiopathic pulmonary fibrosis only in patients with FVC ≥ 50% and DLCO ≥ 30%
- ESBRIET has Marketing Authorisation in the treatment of mild to moderate idiopathic pulmonary fibrosis.
- The efficacy of ESBRIET versus placebo has been demonstrated in an improvement in predicted forced vital capacity: the level of the effect is moderate and its efficacy as regards mortality must be viewed with caution given the numerous methodological limitations.
- It represents only a minor improvement in patients with a forced vital capacity (FVC) ≥ 50% and diffusing capacity for carbon monoxide (DLCO) ≥ 30%.
- Use of ESBRIET necessitates regular monitoring of tolerability and liver enzymes, as well as stopping smoking.
Clinical Benefit
Moderate |
- |
Clinical Added Value
minor |
- |
Therapeutic use
- |
-
Economic analysis
English version
Contact Us
Évaluation des médicaments